The role of epidermal sphingolipids in dermatologic diseases

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Borodzicz, Sonia ^a   Rudnicka, Lidia ^a   Mirowska Guzel, Dagmara ^a   Cudnoch Jedrzejewska, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Atopic dermatitis; Ceramide; Dermatologic diseases; Ichthyosis; Psoriasis; Sphingolipids; Sphingosine 1 phosphate

Indexed keywords

AMINOTRANSFERASE; CERAMIDE DERIVATIVE; LIVER ENZYME; PLACEBO; PONESIMOD; SKIN LIPID; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

ADVERSE DRUG REACTION; AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ATOPIC DERMATITIS; BRADYCARDIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; COUGHING; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EXTRACELLULAR MATRIX; HUMAN; ICHTHYOSIS; KERATINOCYTE; LIPOGENESIS; NONHUMAN; PATHOGENESIS; PRURITUS; PSORIASIS; REGULATORY MECHANISM; REVIEW; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SKIN DISEASE; SKIN PROTECTION; SKIN WATER LOSS; SPHINGOLIPID METABOLISM; STRATUM CORNEUM; WHEEZING; BIOSYNTHESIS; CHEMISTRY; EPIDERMIS; METABOLISM;

EPIDERMIS; HUMANS; SKIN DISEASES; SPHINGOLIPIDS;

EID: 84957805059     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0178-7     Document Type: Review

References (82)

1. Holleran WM, Takagi Y, Uchida Y. Epidermal sphingolipids: metabolism, function, and roles in skin disorders. FEBS Lett. 2006;580(23):5456-66.
2. Geilen CC, Barz S, Bektas M. Sphingolipid signaling in epidermal homeostasis. Current knowledge and new therapeutic approaches in dermatology. Skin Pharmacol Appl Skin Physiol. 2001;14(5):261-71.
3. Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014;71(1):177-84.
4. Lew BL, Cho Y, Kim J, Sim WY, Kim NI. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-9.
5. Cho Y, Lew BL, Seong K, Kim NI. An inverse relationship between ceramide synthesis and clinical severity in patients with psoriasis. J Korean Med Sci. 2004;19(6):859-63.
6. Hong KK, Cho HR, Ju WC, Cho Y, Kim NI. A study on altered expression of serine palmitoyltransferase and ceramidase in psoriatic skin lesion. J Korean Med Sci. 2007;22(5):862-7.
7. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol. 1991;96(4):523-6.
8. Ishikawa J, Narita H, Kondo N, Hotta M, Takagi Y, Masukawa Y, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010;130(10):2511-4.
9. Yamamoto A, Serizawa S, Ito M, Sato Y. Stratum corneum lipid abnormalities in atopic dermatitis. Arch Dermatol Res. 1991;283(4):219-23.
10. Jungersted JM, Høgh JK, Hellgren LI, Wilkinson S, Jemec GB, Agner T. Hand eczema and stratum corneum ceramides. Clin Exp Dermatol. 2015;40(3):243-6.
11. Yamamoto A, Takenouchi K, Ito M. Impaired water barrier function in acne vulgaris. Arch Dermatol Res. 1995;287(2):214-8.
12. Radner FP, Marrakchi S, Kirchmeier P, Kim GJ, Ribierre F, Kamoun B, et al. Mutations in CERS3 cause autosomal recessive congenital ichthyosis in humans. PLoS Genet. 2013;9(6), e1003536.
13. Eckl KM, Tidhar R, Thiele H, Oji V, Hausser I, Brodesser S, et al. Impaired epidermal ceramide synthesis causes autosomal recessive congenital ichthyosis and reveals the importance of ceramide acyl chain length. J Invest Dermatol. 2013;133(9):2202-11.
14. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005;115(7):1777-84.
15. Lavrijsen AP, Bouwstra JA, Gooris GS, Weerheim A, Boddé HE, Ponec M. Reduced skin barrier function parallels abnormal stratum corneum lipid organization in patients with lamellar ichthyosis. J Invest Dermatol. 1995;105(4):619-24.
16. Paige DG, Morse-Fisher N, Harper JI. Quantification of stratum corneum ceramides and lipid envelope ceramides in the hereditary ichthyoses. Br J Dermatol. 1994;131(1):23-7.
17. Reichelt J, Doering T, Schnetz E, Fartasch M, Sandhoff K, Magin AM. Normal ultrastructure, but altered stratum corneum lipid and protein composition in a mouse model for epidermolytic hyperkeratosis. J Invest Dermatol. 1999;113(3):329-34.
18. Jensen JM, Schütze S, Neumann C, Proksch E. Impaired cutaneous permeability barrier function, skin hydration, and sphingomyelinase activity in keratin 10 deficient mice. J Invest Dermatol. 2000;115(4):708-13.
19. Bosen F, Celli A, Crumrine D, Vom Dorp K, Ebel P, Jastrow H, et al. Altered epidermal lipid processing and calcium distribution in the KID syndrome mouse model Cx26S17F. FEBS Lett. 2015;589(15):1904-10.
20. Uchida Y, Cho Y, Moradian S, Kim J, Nakajima K, Crumrine D, et al. Neutral lipid storage leads to acylceramide deficiency, likely contributing to the pathogenesis of Dorfman-Chanarin syndrome. J Invest Dermatol. 2010;130(10):2497-9.
21. van Smeden J, Janssens M, Boiten WA, van Drongelen V, Furio L, Vreeken RJ, et al. Intercellular skin barrier lipid composition and organization in Netherton syndrome patients. J Invest Dermatol. 2014;134(5):1238-45.
22. Jungersted JM, Høgh JK, Hellgren LI, Agner T, Jemec GB. Ceramide profile in hypohidrotic ectodermal dysplasia. Clin Exp Dermatol. 2012;37(2):153-5.
23. Sidransky E, Fartasch M, Lee RE, Metlay LA, Abella S, Zimran A, et al. Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res. 1996;39(1):134-41.
24. Schmuth M, Man MQ, Weber F, Gao W, Feingold KR, Fritsch P, et al. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis. J Invest Dermatol. 2000;115(3):459-66.
25. Airola MV, Hannun YA. Sphingolipid metabolism and neutral sphingomyelinases. Handb Exp Pharmacol. 2013;215:57-76.
26. Khavandgar Z, Murshed M. Sphingolipid metabolism and its role in the skeletal tissues. Cell Mol Life Sci. 2015;72(5):959-69.
27. t'Kindt R, Jorge L, Dumont E, Couturon P, David F, Sandra P, et al. Profiling and characterizing skin ceramides using reversed-phase liquid chromatography-quadrupole time-of-flight mass spectrometry. Anal Chem. 2012;84(1):403-11.
28. Alessandrini F, Pfister S, Kremmer E, Gerber JK, Ring J, Behrendt H. Alterations of glucosylceramide-beta-glucosidase levels in the skin of patients with psoriasis vulgaris. J Invest Dermatol. 2004;123(6):1030-6.
29. Mizutani Y, Mitsutake S, Tsuji K, Kihara A, Igarashi Y. Ceramide biosynthesis in keratinocyte and its role in skin function. Biochimie. 2009;91(6):784-90.
30. Borodzicz S, Czarzasta K, Kuch M, Cudnoch-Jedrzejewska A. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 2015;16(14):55.
31. Uchida Y. Ceramide signaling in mammalian epidermis. Biochim Biophys Acta. 2014;1841(3):453-62.
32. Sayama K, Hanakawa Y, Shirakata Y, Yamasaki K, Sawada Y, Sun L, et al. Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation. J Biol Chem. 2001;276(2):999-1004.
33. Jiang YJ, Kim P, Uchida Y, Elias PM, Bikle DD, Grunfeld C, et al. Ceramides stimulate caspase-14 expression in human keratinocytes. Exp Dermatol. 2013;22(2):113-8.
34. Magnoni C, Euclidi E, Benassi L, Bertazzoni G, Cossarizza A, Seidenari S, et al. Ultraviolet B radiation induces activation of neutral and acidic sphingomyelinases and ceramide generation in cultured normal human keratinocytes. Toxicol In Vitro. 2002;16(4):349-55.
35. Uchida Y, Nardo AD, Collins V, Elias PM, Holleran WM. De novo ceramide synthesis participates in the ultraviolet B irradiation-induced apoptosis in undifferentiated cultured human keratinocytes. J Invest Dermatol. 2003;120(4):662-9.
36. Wakita H, Tokura Y, Yagi H, Nishimura K, Furukawa F, Takigawa M. Keratinocyte differentiation is induced by cell-permeant ceramides and its proliferation is promoted by sphingosine. Arch Dermatol Res. 1994;286(6):350-4.
37. Amen N, Mathow D, Rabionet M, Sandhoff R, Langbein L, Gretz N, et al. Differentiation of epidermal keratinocytes is dependent on glucosylceramide:ceramide processing. Hum Mol Genet. 2013;15(22(20)):4164-79.
38. Vogler R, Sauer B, Kim DS, Schäfer-Korting M, Kleuser B. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J Invest Dermatol. 2003;120(4):693-700.
39. Kim DS, Kim SY, Kleuser B, Schäfer-Korting M, Kim KH, Park KC. Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation. Cell Signal. 2004;16(1):89-95.
40. Wakita H, Matsushita K, Nishimura K, Tokura Y, Furukawa F, Takigawa M. Sphingosylphosphorylcholine stimulates proliferation and upregulates cell surface-associated plasminogen activator activity in cultured human keratinocytes. J Invest Dermatol. 1998;110(3):253-8.
41. Nakajima K, Terao M, Takaishi M, Kataoka S, Goto-Inoue N, Setou M, et al. Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. J Invest Dermatol. 2013;133(11):2555-65.
42. Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R. Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol. 1994;130(4):452-6.
43. Motta S, Monti M, Sesana S, Caputo R, Carelli S, Ghidoni R. Ceramide composition of the psoriatic scale. Biochim Biophys Acta. 1993;1182(2):147-51.
44. Tawada C, Kanoh H, Nakamura M, Mizutani Y, Fujisawa T, Banno Y, et al. Interferon-γ decreases ceramides with long-chain fatty acids: possible involvement in atopic dermatitis and psoriasis. J Invest Dermatol. 2014;134(3):712-8.
45. Alessandrini F, Stachowitz S, Ring J, Behrendt H. The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris. J Invest Dermatol. 2001;116(3):394-400.
46. Moon SH, Kim JY, Song EH, Shin MK, Cho YH, Kim NI. Altered levels of sphingosine and sphinganine in psoriatic epidermis. Ann Dermatol. 2013;25(3):321-6.
47. Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, et al. Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal. 2007;19(4):748-60.
48. Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959):2036-45.
49. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011;337(2):547-56.
50. Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;1(6):109.
51. Park YH, Jang WH, Seo JA, Park M, Lee TR, Park YH, et al. Decrease of ceramides with very long-chain fatty acids and downregulation of elongases in a murine atopic dermatitis model. J Invest Dermatol. 2012;132(2):476-9.
52. Li W, Sandhoff R, Kono M, Zerfas P, Hoffmann V, Ding BC, et al. Depletion of ceramides with very long chain fatty acids causes defective skin permeability barrier function, and neonatal lethality in ELOVL4 deficient mice. Int J Biol Sci. 2007;3(2):120-8.
53. van Smeden J, Janssens M, Kaye EC, Caspers PJ, Lavrijsen AP, Vreeken RJ, et al. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol. 2014;23(1):45-52.
54. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78(1):27-30.
55. Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002;119(1):166-73.
56. Sugiura A, Nomura T, Mizuno A, Imokawa G. Reevaluation of the non-lesional dry skin in atopic dermatitis by acute barrier disruption: an abnormal permeability barrier homeostasis with defective processing to generate ceramide. Arch Dermatol Res. 2014;306(5):427-40.
57. Farwanah H, Raith K, Neubert RH, Wohlrab J. Ceramide profiles of the uninvolved skin in atopic dermatitis and psoriasis are comparable to those of healthy skin. Arch Dermatol Res. 2005;296(11):514-21.
58. Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res. 2012;53(12):2755-66.
59. Bleck O, Abeck D, Ring J, Hoppe U, Vietzke JP, Wolber R, et al. Two ceramide subfractions detectable in Cer(AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema. J Invest Dermatol. 1999;113(6):894-900.
60. Angelova-Fischer I, Mannheimer AC, Hinder A, Ruether A, Franke A, Neubert RH, et al. Distinct barrier integrity phenotypes in filaggrin-related atopic eczema following sequential tape stripping and lipid profiling. Exp Dermatol. 2011;20(4):351-6.
61. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuentes L, Høgh JK, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010;65(7):911-8.
62. Imokawa G. A possible mechanism underlying the ceramide deficiency in atopic dermatitis: expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. J Dermatol Sci. 2009;55(1):1-9.
63. Jin K, Higaki Y, Takagi Y, Higuchi K, Yada Y, Kawashima M, et al. Analysis of beta-glucocerebrosidase and ceramidase activities in atopic and aged dry skin. Acta Derm Venereol. 1994;74(5):337-40.
64. Ohnishi Y, Okino N, Ito M, Imayama S. Ceramidase activity in bacterial skin flora as a possible cause of ceramide deficiency in atopic dermatitis. Clin Diagn Lab Immunol. 1999;6(1):101-4.
65. Kita K, Sueyoshi N, Okino N, Inagaki M, Ishida H, Kiso M, et al. Activation of bacterial ceramidase by anionic glycerophospholipids: possible involvement in ceramide hydrolysis on atopic skin by Pseudomonas ceramidase. Biochem J. 2002;362(Pt 3):619-26.
66. Jensen JM, Fölster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C, et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol. 2004;122(6):1423-31.
67. Cui CY, Kusuda S, Seguchi T, Takahashi M, Aisu K, Tezuka T. Decreased level of prosaposin in atopic skin. J Invest Dermatol. 1997;109(3):319-23.
68. Sawada E, Yoshida N, Sugiura A, Imokawa G. Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitis. J Dermatol Sci. 2012;68(1):25-35.
69. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol. 2002;119(2):433-9.
70. Akiyama M. The roles of ABCA12 in keratinocyte differentiation and lipid barrier formation in the epidermis. Dermatoendocrinol. 2011;3(2):107-12.
71. Zuo Y, Zhuang DZ, Han R, Isaac G, Tobin JJ, McKee M, et al. ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters. J Biol Chem. 2008;283(52):36624-35.
72. Yanagi T, Akiyama M, Nishihara H, Ishikawa J, Sakai K, Miyamura Y, et al. Self-improvement of keratinocyte differentiation defects during skin maturation in ABCA12-deficient harlequin ichthyosis model mice. Am J Pathol. 2010;177(1):106-18.
73. Epp N, Fürstenberger G, Müller K, de Juanes S, Leitges M, Hausser I, et al. 12R-lipoxygenase deficiency disrupts epidermal barrier function. J Cell Biol. 2007;177(1):173-82.
74. Krieg P, Rosenberger S, de Juanes S, Latzko S, Hou J, Dick A, et al. Aloxe3 knockout mice reveal a function of epidermal lipoxygenase-3 as hepoxilin synthase and its pivotal role in barrier formation. J Invest Dermatol. 2013;133(1):172-80.
75. Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013;351(2):289-300.
76. Nakajima K, Sano S, Uchida Y, Akiyama M, Morita Y, Shimizu H. Altered lipid profiles in the stratum corneum of Sjögren-Larsson syndrome. J Dermatol Sci. 2011;63(1):64-6.
77. Chan A, Holleran WM, Ferguson T, Crumrine D, Goker-Alpan O, Schiffmann R, et al. Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications. Mol Genet Metab. 2011;104(4):631-6.
78. Doering T, Proia RL, Sandhoff K. Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice. FEBS Lett. 1999;447(2-3):167-70.
79. Uchida Y, Hara M, Nishio H, Sidransky E, Inoue S, Otsuka F, et al. Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J Lipid Res. 2000;41(12):2071-82.
80. Holleran WM, Ginns EI, Menon GK, Grundmann JU, Fartasch M, McKinney CE, et al. Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest. 1994;93(4):1756-64.
81. Vanier MT. Niemann-pick diseases. Handb Clin Neurol. 2013;113:1717-21.
82. Pavicic T, Wollenweber U, Farwick M, Korting HC. Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. Int J Cosmet Sci. 2007;29(3):181-90.